These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 38305755)
1. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas. Polgarova K; Trneny M Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755 [TBL] [Abstract][Full Text] [Related]
2. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857 [TBL] [Abstract][Full Text] [Related]
3. Glofitamab: First Approval. Shirley M Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013 [TBL] [Abstract][Full Text] [Related]
4. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690 [TBL] [Abstract][Full Text] [Related]
5. The value of bispecific antibodies in relapsed and refractory DLBCL. Lewis KL; Cheah CY Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535 [TBL] [Abstract][Full Text] [Related]
6. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732 [No Abstract] [Full Text] [Related]
7. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996 [TBL] [Abstract][Full Text] [Related]
8. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. Wang C; Liu Y J Hematol Oncol; 2023 Mar; 16(1):20. PubMed ID: 36895020 [TBL] [Abstract][Full Text] [Related]
9. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963 [TBL] [Abstract][Full Text] [Related]
10. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma. Cassanello G; Luna de Abia A; Falchi L Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082 [TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma. Ahmed G; Furqan F; Nasrollahi E; Hamadani M Expert Rev Anticancer Ther; 2024 Aug; 24(8):705-715. PubMed ID: 38809821 [TBL] [Abstract][Full Text] [Related]
12. Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report. Loap P; Johnson N; Birsen R; Decroocq J; Kirova Y Strahlenther Onkol; 2024 Nov; 200(11):983-985. PubMed ID: 38955824 [TBL] [Abstract][Full Text] [Related]
13. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan. Hsu YT; Wu SJ; Kao HW; Hsiao SY; Liao CK; Chen TY; Wang MC Cancer; 2024 Jun; 130(11):1972-1981. PubMed ID: 38306242 [TBL] [Abstract][Full Text] [Related]
14. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. González Barca E Front Immunol; 2022; 13():909008. PubMed ID: 35928819 [TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709 [TBL] [Abstract][Full Text] [Related]
16. Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss. Carlo-Stella C Br J Haematol; 2024 Jul; 205(1):17-19. PubMed ID: 38813657 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Doraiswamy A; Shah MR; Bannerji R Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641 [TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
19. [Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment]. Daguerre V; Croizier C Bull Cancer; 2024 Sep; 111(9):794-796. PubMed ID: 38876895 [No Abstract] [Full Text] [Related]
20. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Phillips TJ; Carlo-Stella C; Morschhauser F; Bachy E; Crump M; Trněný M; Bartlett NL; Zaucha J; Wrobel T; Offner F; Humphrey K; Relf J; Filézac de L'Etang A; Carlile DJ; Byrne B; Qayum N; Lundberg L; Dickinson M J Clin Oncol; 2024 Oct; ():JCO2302470. PubMed ID: 39365960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]